|Other names||D-16726; NSC-341952|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||351.402 g·mol−1|
|3D model (JSmol)|
Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed. It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials. Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs, and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414. Zindoxifene was first described in 1984.
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1300–. ISBN 978-1-4757-2085-3.
- Maximov PY, McDaniel RE, Jordan VC (23 July 2013). "The Legacy of Tamoxifen". Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 170–. ISBN 978-3-0348-0664-0.
- McDaniel R, Maximov PY, Jordan VC (25 June 2013). "The Legacy of Tamoxifen". In Litwack G (ed.). Hormones and Breast Cancer. Elsevier. pp. 32–. ISBN 978-0-12-416676-9.
- Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 68–69. ISBN 978-3-642-58616-3.
- Maggi A, Paoletti R (2002). "The Pharmacological Modulations of Estrogen Receptor Activity". International position paper on women's health and menopause : a comprehensive approach. DIANE Publishing. pp. 111–. ISBN 978-1-4289-0521-4.